IL17A and psoriatic arthritis: The selective blockade of IL-17A through secukinumab or ixekizumab, causing a simultaneous neutralization of IL-17AA homodimers and IL-17AF heterodimers, has shown a fast and constant efficacy in the treatment of plaque-type psoriasis, nail psoriasis and psoriatic arthritis [3,4,9,10].